1. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study
- Author
-
Kurt R. Oettel, Abraham S. Kanate, Suzanne R. Hayman, Judith Manola, S. Vincent Rajkumar, Sagar Lonial, Joseph R. Mikhael, and Amylou C. Dueck
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,Renal function ,Kidney Function Tests ,lcsh:RC254-282 ,Article ,Dexamethasone ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,In patient ,Renal Insufficiency ,Lenalidomide ,Survival analysis ,Multiple myeloma ,Dialysis ,Aged ,Aged, 80 and over ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,Survival Analysis ,Clinical trial ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Female ,Drug Monitoring ,business ,Multiple Myeloma ,Biomarkers ,030215 immunology ,medicine.drug - Abstract
Renal insufficiency is common in patients with relapsed multiple myeloma and can often limit choice of therapy. Lenalidomide, a critical agent in the treatment of relapsed multiple myeloma, is renally cleared., This phase I/II trial evaluated the efficacy and safety of lenalidomide with dexamethasone in patients with relapsed multiple myeloma and renal insufficiency. Three groups were treated, with creatinine clearance 30–60 cc/hr (group A), CrCl 30, and can be given daily to those with CrCl
- Published
- 2018